Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up
Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up
复制标题
DOI：
10.1111/j.1365-2141.2005.05667.x
复制
发表时间：
2005-09-01
影响因子：
6.5
通讯作者：
Storb, R
中科院分区：
文献类型：
--
作者：
Kahl, C;Leisenring, W;Storb, R
对81例2-63岁的重型再生障碍性贫血患者，在环磷酰胺+抗胸腺细胞球蛋白后，接受了人白细胞抗原匹配的相关骨髓移植，移植后接受了甲氨蝶呤+环孢素。中位随访时间为9.2年。96%的患者持续植入，24%的患者发生急性移植物抗宿主病（GVHD），除2例患者外均为11级，26%的患者发生慢性GVHD;所有存活患者最终对免疫抑制治疗有反应。6名患者患上了癌症：1名致命性淋巴瘤和5名癌症（所有5名患者现在都没有癌症）。存活率为88%。该方案在接受过大量预治疗的再生障碍性贫血患者中耐受性良好且有效。
A total of 81 severe aplastic anaemia patients, aged 2-63 years, received human leucocyte antigen-matched related marrow grafts after cyclophosphamide + antithymocyte globulin followed by postgrafting methotrexate + ciclosporin. Median follow-up was 9.2 years. Ninety-six per cent of patients had sustained engraftment, 24% developed acute graft-versus-host disease (GVHD), grade 11 in all but two patients, and 26% developed chronic GVHD; all surviving patients eventually responded to immunosuppressive therapy. Six patients developed cancer: one fatal lymphoma and five carcinomas (all five patients are now free of cancer). Survival was 88%. The regimen appeared well tolerated and effective in heavily pretreated patients with aplastic anaemia.